Sun Pharma Q3 Net Profit Jumps 16% to Rs 3,368.8 Cr; Declares Rs 11 Dividend

• Sun Pharmaceutical Industries Ltd reported a 16% year-on-year rise in net profit for Q3, reaching Rs 3,368.8 crore.
• The company declared an interim dividend of Rs 11 per equity share for FY26, with the record date set for February 5, 2026.
• Revenue from operations increased by 13.5% to Rs 15,520.5 crore, exceeding Street estimates.
• EBITDA rose 23.4% to Rs 4,984.4 crore, with operating margin expanding to 31.9%.
• Global innovative medicines business sales reached $423 million, contributing 21.2% to overall sales.

Why It Matters: Sun Pharma delivered strong Q3 results with significant profit and revenue growth, along with an interim dividend.